Literature DB >> 17333392

The evolving role of drug metabolism in drug discovery and development.

Lilian G Yengi1, Louis Leung, John Kao.   

Abstract

Drug metabolism in pharmaceutical research has traditionally focused on the well-defined aspects of absorption, distribution, metabolism and excretion, commonly-referred to ADME properties of a compound, particularly in the areas of metabolite identification, identification of drug metabolizing enzymes (DMEs) and associated metabolic pathways, and reaction mechanisms. This traditional emphasis was in part due to the limited scope of understanding and the unavailability of in vitro and in vivo tools with which to evaluate more complex properties and processes. However, advances over the past decade in separate but related fields such as pharmacogenetics, pharmacogenomics and drug transporters, have dramatically shifted the drug metabolism paradigm. For example, knowledge of the genetics and genomics of DMEs allows us to better understand and predict enzyme regulation and its effects on exogenous (pharmacokinetics) and endogenous pathways as well as biochemical processes (pharmacology). Advances in the transporter area have provided unprecedented insights into the role of transporter proteins in absorption, distribution, metabolism and excretion of drugs and their consequences with respect to clinical drug-drug and drug-endogenous substance interactions, toxicity and interindividual variability in pharmacokinetics. It is therefore essential that individuals involved in modern pharmaceutical research embrace a fully integrated approach and understanding of drug metabolism as is currently practiced. The intent of this review is to reexamine drug metabolism with respect to the traditional as well as current practices, with particular emphasis on the critical aspects of integrating chemistry and biology in the interpretation and application of metabolism data in pharmaceutical research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333392     DOI: 10.1007/s11095-006-9217-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  190 in total

Review 1.  Cross-species sequence comparisons: a review of methods and available resources.

Authors:  Kelly A Frazer; Laura Elnitski; Deanna M Church; Inna Dubchak; Ross C Hardison
Journal:  Genome Res       Date:  2003-01       Impact factor: 9.043

2.  THE LIGHT REVERSIBLE CARBON MONOXIDE INHIBITION OF THE STEROID C21-HYDROXYLASE SYSTEM OF THE ADRENAL CORTEX.

Authors:  R W ESTABROOK; D Y COOPER; O ROSENTHAL
Journal:  Biochem Z       Date:  1963

3.  Prescribing BiDil: is it black and white?

Authors:  Susanne B Haga; Geoffrey S Ginsburg
Journal:  J Am Coll Cardiol       Date:  2006-06-09       Impact factor: 24.094

4.  Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor.

Authors:  George H Searfoss; William H Jordan; David O Calligaro; Elizabeth J Galbreath; Linda M Schirtzinger; Brian R Berridge; Hong Gao; Marnie A Higgins; Patrick C May; Timothy P Ryan
Journal:  J Biol Chem       Date:  2003-08-29       Impact factor: 5.157

5.  Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Authors:  George K Dresser; David G Bailey; Brenda F Leake; Ute I Schwarz; Paul A Dawson; David J Freeman; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

6.  Evidence for superoxide generation by NADPH-cytochrome c reductase of rat liver microsomes.

Authors:  S D Aust; D L Roerig; T C Pederson
Journal:  Biochem Biophys Res Commun       Date:  1972-06-09       Impact factor: 3.575

7.  Cytochrome P-450 of liver microsomes--one pigment or many.

Authors:  A Hildebrandt; H Remmer; R W Estabrook
Journal:  Biochem Biophys Res Commun       Date:  1968-03-27       Impact factor: 3.575

8.  Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences.

Authors:  Jeffrey F Waring; Guy Cavet; Robert A Jolly; Jeff McDowell; Hongye Dai; Rita Ciurlionis; Chunsheng Zhang; Roland Stoughton; Pek Lum; Allan Ferguson; Christopher J Roberts; Roger G Ulrich
Journal:  EHP Toxicogenomics       Date:  2003-01

9.  The effect of medroxyprogesterone acetate on the hepatic drug-metabolizing enzymes in normal and protein-deficient female rats.

Authors:  J P Nagpal; K L Khanduja; R R Sharma; S Majumdar; R Singh; M P Gupta; S C Dogra
Journal:  Biochem Med       Date:  1985-08

10.  Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative.

Authors:  Gang Luo; Jianrong Lin; William D Fiske; Renke Dai; Tian J Yang; Sean Kim; Michael Sinz; Edward LeCluyse; Eric Solon; James M Brennan; Irma H Benedek; Summer Jolley; Darryl Gilbert; Lifei Wang; Frank W Lee; Liang-Shang Gan
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

View more
  5 in total

Review 1.  Advances in computationally modeling human oral bioavailability.

Authors:  Junmei Wang; Tingjun Hou
Journal:  Adv Drug Deliv Rev       Date:  2015-01-09       Impact factor: 15.470

Review 2.  Comparative metabolism as a key driver of wildlife species sensitivity to human and veterinary pharmaceuticals.

Authors:  Thomas H Hutchinson; Judith C Madden; Vinny Naidoo; Colin H Walker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-11-19       Impact factor: 6.237

Review 3.  Modeling bioavailability to organs protected by biological barriers.

Authors:  Nadia Quignot
Journal:  In Silico Pharmacol       Date:  2013-05-31

4.  Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-Hypnotic Compound.

Authors:  Zhihao Liu; Yakun Yang; Li Sheng; Yan Li
Journal:  Front Pharmacol       Date:  2017-08-11       Impact factor: 5.810

5.  Semiconductor photocatalysis to engineering deuterated N-alkyl pharmaceuticals enabled by synergistic activation of water and alkanols.

Authors:  Zhaofei Zhang; Chuntian Qiu; Yangsen Xu; Qing Han; Junwang Tang; Kian Ping Loh; Chenliang Su
Journal:  Nat Commun       Date:  2020-09-18       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.